Laboratory of Clinical Virology, Faculty of Medicine, University of Crete, 71409 Heraklion, Crete, Greece.
Cardiovasc Res. 2009 Dec 1;84(3):353-60. doi: 10.1093/cvr/cvp241. Epub 2009 Jul 18.
Since the establishment of the inflammatory basis of atherosclerosis, several pro- or anti-inflammatory agents have been examined as potential mediators of the biochemical pathways of lesion formation. Interleukin (IL)-8 was first characterized in 1987. Since then, knowledge regarding its role in leucocyte trafficking and activation has advanced rapidly, especially in the field of cardiovascular disease. In the scientific literature, there is sufficient evidence to support beyond any doubt the involvement of IL-8 in the establishment and preservation of the inflammatory micro-environment of the insulted vascular wall. However, how the information derived from in vitro studies and animal models can be applied in clinical practice has yet to be determined. In the present review, the available evidence regarding the role of IL-8 in cardiovascular disease is presented, and future perspectives are discussed.
自动脉粥样硬化的炎症基础确立以来，人们已经研究了几种促炎或抗炎药物，将其作为病变形成生化途径的潜在介质。白细胞介素 (IL)-8 于 1987 年首次被描述。从那时起，关于其在白细胞迁移和激活中的作用的知识迅速发展，特别是在心血管疾病领域。在科学文献中，有充分的证据毋庸置疑地支持 IL-8 参与受损血管壁炎症微环境的建立和维持。然而，如何将体外研究和动物模型得出的信息应用于临床实践尚待确定。在本综述中，介绍了 IL-8 在心血管疾病中的作用的现有证据，并讨论了未来的展望。
